Levemir

Insulin detemir

DM in adults, adolescents & childn ≥1 yr.

SC In combination w/ oral antidiabetic agents or GLP-1 receptor agonists Adult Initially 0.1-0.2 u/kg or 10 u once daily. Titrate dose based on individual patient's needs. As part of a basal-bolus insulin regimen Administer once daily or bd depending on patient's needs. Adjust dose individually.

May be taken with or without food.

Hypersensitivity.

Must not be administered via IV. Avoid IM administration. Do not use in insulin infusion pumps. Inj site reactions (including lipodystrophy & cutaneous amyloidosis) may occur. Perform continuous rotation of inj sites w/in the same region. Blood glucose monitoring is recommended after change in the inj site from an affected area (inj site w/ lipodystrophy, cutaneous amyloidosis) to an unaffected area, & dose adjustment of antidiabetic medications may be considered. Dose adjustment may be necessary if patients undertake increased physical activity, change their usual diet, or during concomitant illness (especially infections & feverish conditions; concomitant diseases in the kidney, liver or affecting the adrenal, pituitary or thyroid gland). Close glucose monitoring is recommended when transferring from other insulin medicinal products (change in strength, brand, type, origin &/or method of manufacture) & in the initial wk thereafter. Risk of hyperglycaemia & diabetic ketoacidosis w/ inadequate dosing or treatment discontinuation, especially in type 1 diabetes. Risk of hypoglycaemia w/ excessive insulin dose, omitted meal, or unplanned, strenuous physical exercise. Must not be injected in case of hypoglycaemia or if hypoglycaemia is suspected. Change in usual warning symptoms of hypoglycaemia in patients w/ greatly improved blood glucose control (eg, by intensified insulin therapy); disappearance of usual warning symptoms in patients w/ longstanding diabetes. Careful monitoring is recommended in patients w/ severe hypoalbuminaemia. Reports of cardiac failure when used in combination w/ pioglitazone, especially in patients w/ risk factors for development of cardiac heart failure. May impair ability to drive or operate machinery. Intensify glucose monitoring & adjust Levemir dose on an individual basis in patients w/ renal or hepatic impairment, adolescents & childn >1 yr, & the elderly. Pregnancy & lactation. May require adjustments in insulin dose & diet in breast-feeding women. Safety & efficacy in childn <1 yr have not been established.

Hypoglycaemia. Inj site reactions.

Reduced insulin requirements w/ oral antidiabetics, GLP-1 receptor agonists, MAOIs, β-blockers, ACE inhibitors, salicylates, anabolic steroids & sulphonamides. Increased insulin requirements w/ OCs, thiazides, glucocorticoids, thyroid hormones, sympathomimetics, growth hormone & danazol. Masked symptoms of hypoglycaemia w/ β-blockers. Increased or decreased insulin requirement w/ octreotide/lanreotide. Intensified or reduced hypoglycaemic effect w/ alcohol.

Insulin Preparations

A10AE05 - insulin detemir ; Belongs to the class of long-acting insulins and analogues for injection. Used in the treatment of diabetes.

P₁